Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A woman with type 2 diabetes developed alopecia areata, suggesting a link between the two autoimmune conditions.

This study found that abnormal carbohydrate metabolism linked to increased serum fasting insulin levels is associated with 20% of women with polycystic ovary syndrome, and these women exhibit more symptoms compared to those with normal insulin levels.

In this study, treatment with insulin sensitizers significantly increased adipose tissue GLUT4 mRNA expression and improved insulin resistance, menstrual patterns, and androgen profiles in PCOS patients, with rosiglitazone being more effective than metformin.

This study found that diabetic individuals experienced significant changes in hair characteristics, including reduced thickness, strength, and altered growth cycle phases, correlated with poor glycaemic control and haematological variations compared to healthy controls.

This study found that for obese patients undergoing sleeve gastrectomy, concurrent type 2 diabetes is linked to worsened metabolic but milder reproductive aspects of PCOS and does not hinder the return to regular menstruation one year after surgery.

This study found that hair analysis is an effective non-invasive method for assessing metabolic fluctuations, showing stable advanced glycation end products levels that correlate with age and differ significantly between diabetic and non-diabetic rats.

Alloxan diabetes, methylthiouracil, cortisone, and adrenaline affect how white mice hair follicles use glucose and cystine and their cell division.

This study suggests that metformin might serve as a diagnostic and therapeutic option to distinguish insulin resistance-related ovarian testosterone excess from a testosterone-secreting tumor in women with virilization.

This case series reports three cats diagnosed with hypersomatotropism due to GH-secreting pituitary adenomas without concurrent diabetes mellitus, highlighting the potential for underdiagnosis in non-diabetic cats.

This study suggests that metformin has a stronger impact on gonadotroph hormone levels in men with early-onset androgenic alopecia compared to those with normal hair growth.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

This study developed a novel hydrogel that improved healing in diabetic infected wounds on mobile sites by controlling infection, inflammation, and mechanical stress, promoting skin regeneration without excess scarring.

This study found that nonobese women with idiopathic hirsutism had higher fibrinogen levels and lower nitrite/nitrate concentrations compared to controls, similar to those with PCOS.

This study found that in overweight or obese women with PCOS and insulin resistance, those with lower baseline prolactin levels exhibited a greater decrease in insulin resistance after 6-8 months of metformin treatment, compared to those with higher prolactin levels.

This review discusses the lack of long-term clinical studies on metformin's cardiovascular benefits in women with polycystic ovary syndrome, highlighting lifestyle changes as a crucial management strategy for reducing associated risks.

In this study, patients with androgenic alopecia were found to have higher levels of insulin, glucose, and HOMA-IR compared to healthy individuals, suggesting distinct metabolic profiles that may contribute to the condition's development.

This review discusses the high prevalence of androgen excess and PCOS in women with type 1 diabetes but reports no new clinical findings; the authors highlight the underdiagnosis of hyperandrogenism in these patients.

In this study, men with pre-diabetes seeking treatment for erectile dysfunction had worse hormonal and metabolic profiles and a higher risk of severe erectile dysfunction compared to those without pre-diabetes.

This article describes a case of severe hyperandrogenism in a 35-year-old woman where high-resolution imaging ruled out tumors, and treatment with cyproterone acetate normalized testosterone levels.

In this study, Neogynon was found to be 100% effective as a contraceptive, with no observed failures in 3129 cycles among 184 women, while side effects included changes in endometrial patterns and some central nervous system effects.

In this study, long-term normalization of testosterone levels in postmenopausal women with hyperandrogenism did not improve body mass index, glucose, or lipid metabolism.

This study suggests that adding metformin to diet and exercise improves insulin resistance and hyperandrogenism in women with PCOS, though lifestyle changes alone may enhance menstrual cycles.

This study found that women with polycystic ovary syndrome have higher triglyceride and fasting glucose levels in obese individuals and higher total cholesterol levels in non-obese individuals compared to healthy women.

Gestational diabetes increases risks for mothers and babies, needing early diagnosis and care.

This study highlights the need to prioritize early prevention of type 2 diabetes mellitus by focusing on early pathophysiologic mechanisms such as insulin resistance, rather than hyperglycemia, as conditions like non-alcoholic fatty liver disease and polycystic ovarian syndrome are early indicators of future diabetes risk.

This study found that metformin's metabolic benefits, such as reducing fat content and improving insulin sensitivity, were less pronounced in men with early-onset androgenic alopecia compared to those with normal hair growth, possibly due to differences in systemic inflammation and vitamin D status.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

In this study, GLP-1 receptor agonists reduced BMI and improved metabolic and reproductive outcomes in women with PCOS, though the long-term effects remain unclear.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.